Company research
Nanobiotix S.A.
CIK 1760854Updated Sep 24, 2026
SecuritiesNNBXF · OTC · equityNBTX · NASDAQ · adr
NNBXF price & chart
Loading TradingView…
OTC:NNBXF on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossEUR | -23,961,000Source | -68,132,000Source | -39,700,000Source | -57,041,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableEUR | 840,000Source | -2,070,000Source | -806,000Source | -101,000Source |
| AdjustmentsForFinanceCostsEUR | 4,088,000Source | 1,942,000Source | 2,714,000Source | 2,042,000Source |
| AdjustmentsForIncomeTaxExpenseEUR | 3,000Source | 101,000Source | 120,000Source | — |
| AdjustmentsForSharebasedPaymentsEUR | 3,539,000Source | 4,298,000Source | 3,222,000Source | 3,174,000Source |
| IncreaseDecreaseInWorkingCapitalEUR | 3,402,000Source | -14,283,000Source | -9,920,000Source | -2,300,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | 1,530,000Source | 980,000Source | 6,978,000Source | 915,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | 1,195,000Source | 1,080,000Source | 794,000Source | 1,093,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | 42,933,000Source | 0Source | 150,000Source | 0Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | 8,000Source | 2,000Source | 9,000Source | 1,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | 3,549,000Source | 3,075,000Source | 2,971,000Source | 3,642,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Selling, General and Administrative ExpenseEUR | 20,360,000Source | 20,527,000Source | 22,049,000Source | 17,857,000Source |
| Total RevenueEUR | 32,593,000Source | -7,191,000Source | 36,207,000Source | 4,776,000Source |
| Additional Financial Items | ||||
| ApplicableTaxRatenumber | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| AverageEffectiveTaxRatenumber | 0Source | -0Source | -0Source | 0Source |
| BasicEarningsLossPerShareEUR/shares | -0.5Source | -1.44Source | -1.08Source | -1.64Source |
| DilutedEarningsLossPerShareEUR/shares | -0.5Source | -1.44Source | -1.08Source | -1.64Source |
| EmployeeBenefitsExpenseEUR | 24,432,000Source | 24,331,000Source | 22,493,000Source | 20,556,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | 3,539,000Source | 4,298,000Source | 3,222,000Source | 3,174,000Source |
| FinanceCostsEUR | 15,233,000Source | 7,488,000Source | 14,803,000Source | 13,863,000Source |
| FinanceIncomeEUR | 2,092,000Source | 7,849,000Source | 2,002,000Source | 3,533,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | 3,000Source | 101,000Source | 120,000Source | 10,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | 130,000Source | 170,000Source | 203,000Source | 238,000Source |
| OtherFinanceCostEUR | 16,000Source | — | — | — |
| OtherIncomeEUR | 2,950,000Source | 4,419,000Source | 6,150,000Source | 4,776,000Source |
| OtherOperatingIncomeExpenseEUR | 64,000Source | -134,000Source | -2,542,000Source | -985,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | 95,000Source | 76,000Source | 75,000Source | 78,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | -23,961,000Source | -68,132,000Source | -39,700,000Source | -57,041,000Source |
| ProfitLossBeforeTaxEUR | -23,961,000Source | -68,132,000Source | -39,700,000Source | -57,041,000Source |
| ProfitLossFromOperatingActivitiesEUR | -10,818,000Source | -68,392,000Source | -26,779,000Source | -46,702,000Source |
| ResearchAndDevelopmentExpenseEUR | 23,115,000Source | 40,541,000Source | 38,396,000Source | 32,636,000Source |
Filing attachments
ny20063216x3_ex107.htm · 424B5 · 2026-05-22
EXHIBIT 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $99,903,070.97.
Read attachment ↗